ANGION IS A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY
TARGETING ACUTE AND CHRONIC ORGAN INJURY.
Our pioneering work in rational drug design optimizes the natural protective, reparative, and regenerative pathways of the body in both orphan diseases and larger clinical indications.
ANGION HAS ONGOING CLINICAL TRIALS IN TWO FORMS OF ACUTE KIDNEY INJURY:
- Phase III clinical trial for Delayed Graft Function post kidney transplantation (DGF-AKI)
- Phase II trial in Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI)
ANGION’S PRECLINICAL PIPELINE USES PRECISION MEDICINE TO TARGET:
- Chronic Organ Disease
- Fibrotic Injuries
- Inflammatory Injuries
CORPORATE OVERVIEW AT the 8th Annual SVB Leerink Health Care Conference
Angion Awarded $4.76 Million Department of Defense Grant for Chronic Kidney Disease Drug Candidate ANG-3070
Angion Completes Equity Financing and Appoints Senior Executives
Angion Biomedica to present at Piper Jaffray Healthcare Conference